Haijun Zhong

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Journal: Future oncology (London, England)

Published: May 28, 2026

Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors.

Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors.

Journal: British journal of hospital medicine (London, England : 2005)

Published: September 30, 2025

A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.

A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 07, 2025

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.

Journal: Therapeutic advances in medical oncology

Published: March 10, 2025

Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study.

Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study.

Journal: Cancer cell

Published: November 28, 2024

Immune checkpoint inhibitors plus paclitaxel-based chemotherapy vs. oxaliplatin-based therapy as first-line treatment for patients with HER2-negative unresectable or metastatic gastric/gastroesophageal junction cancer: results of a multicenter retrospective study.

Immune checkpoint inhibitors plus paclitaxel-based chemotherapy vs. oxaliplatin-based therapy as first-line treatment for patients with HER2-negative unresectable or metastatic gastric/gastroesophageal junction cancer: results of a multicenter retrospective study.

Journal: Translational cancer research

Published: June 27, 2024

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.

Journal: Nature medicine

Published: March 05, 2024

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.

Journal: The oncologist

Published: January 15, 2024

Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.

Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.

Journal: Journal of gastrointestinal oncology

Published: September 29, 2023

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 30, 2023

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.

Journal: The Lancet. Oncology

Published: May 18, 2023

Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.

Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.

Journal: Nature medicine

Published: May 15, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026